Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab

NCT01238029 is registered in ClinicalTrials.gov with Sponsor GmbH as lead sponsor.

NCT NCT01238029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01238029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combinational Therapy of Capecitabine, Lapatinib and Vinorelbine for the Treatment of Patients With her2/Neu Positive, Relapsed or Metastatic Breast Carcinoma Following Treatment Failure With Trastuzumab
Lead sponsor
Sponsor GmbH
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2010
Completion date
July 31, 2014
Enrollment
12 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

failure or contraindication of trastuzumab therapy, first or second line therapy, her2 positive, metastatic breast cancer